Liposomal drug delivery: A versatile platform for challenging clinical applications

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 17, Issue 3, 2014, Pages 401-426

  Madni, M Asadullah ^a   Sarfraz, Muhammad ^b   Rehman, Mubashar ^a   Ahmad, Mahmood ^a   Akhtar, Naveed ^a   Ahmad, Saeed ^a   Tahir, Nayab ^a   Ijaz, Shakeel ^a   Al Kassas, Raida ^c   Löbenberg, Raimar ^b  

^a THE ISLAMIA UNIVERSITY OF BAHAWALPUR   (Pakistan)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cancer treatment; Clinical applications; Drug delivery; Drug targeting; Liposomes; Micelle systems

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ARCHEOSOME; COCHELATE; CUBOSOME; CYTARABINE; DAUNORUBICIN; DIAGNOSTIC AGENT; DOXORUBICIN; ETHOSOME; GAS CONTAINING LIPOSOME; HEPATITIS A VACCINE; IMMUNOLIPOSOME; IMMUNOSOME; INFLUENZA VACCINE; ISCOM; LIPOPLEX; LIPOSOME; MAGNETIC LIPOSOME; MORPHINE SULFATE; NIOSOME; PH SENSITIVE LIPOSOME; POLYMERIZED LIPOSOME; PROLIPOSOME; TEMPERATURE SENSITIVE LIPOSOME; TRANSFEROSOME; UNCLASSIFIED DRUG; VERTEPORFIN; VINCRISTINE SULFATE; VIROSOME;

AQUEOUS SOLUTION; ARTICLE; CANCER CHEMOTHERAPY; DRUG INDICATION; DRUG PENETRATION; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; EXOSOME; GENE THERAPY; HYDROPHOBICITY; LIPID BILAYER; LIPOSOMAL DELIVERY; MOLECULAR DIAGNOSIS; NONHUMAN; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES;

EID: 84908131933     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3cp55     Document Type: Article

References (234)

1. Bangham, A. D., Horne, R.W. Negative staining of phospholipids and their structural modification by surface active agents as observed in the electron microscope. J Mol Biol, 1964; 8: 660- 668.
2. Heap B, Gregoriadis G. Alec Douglas Bangham. 10 November 1921-9 March 2010. Biogr Mems Fell R Soc, 2011; 57:25-43.
3. Gregoriadis G, Leathwood PD, Ryman BE. Enzyme entrapment in liposomes. FEBS Lett, 1971; 14:95-99.
4. Rahman YE, Rosenthal MW, Cerny EA, Moretti ES. Preparation and prolonged tissue retention of liposome encapsulated chelating agents. J Lab Clin Med, 1974; 83:640-647.
5. Chaize B, Colletier JP, Winterhalter M, Fournier D. Encapsulation of enzymes in liposomes: high encapsulation efficiency and control of substrate permeability. Artif Cells Blood Substit Immobil Biotechnol, 2004; 32:67-75.
6. Rooijen N, Nieuwmegen R. Liposomes in immunology: multilamellar phosphatidylcholine liposome as a simple biodegradable and harmless adjuvant without any immunogenic activity of its own. Immunol commun, 1980; 9:243-256.
7. Dai Y, Zhou R, Liu L, Lu Y, Qi J, Wu W. Liposomes containing bile salts as novel ocular delivery systems for tacrolimus (FK506): in vitro characterization and improved corneal permeation. Int J Nanomedicine, 2013; 8:1921-33.
8. Yang Q, Ma Y, Zhao Y, She Z, Wang L, Li J, Wang C, Deng Y. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy. Int J Nanomedicine, 2013; 8:1257-1268.
9. Drummond DC, Meyer O, Hong K. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev, 1999; 51;691- 743.
10. Gill SE, Savage K, Wysham WZ, Blackhurst DW, Winter WE, Puls LE. Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: Is it necessary? Gynecol Oncol, 2013; 129(3): 544-47.
11. Hatakeyama H, Akita H, Harashima H. The Polyethyleneglycol Dilemma: Advantage and Disadvantage of PEGylation of Liposomes for Systemic Genes and Nucleic Acids Delivery to Tumors. Biol Pharm Bull, 2013; 36(6): 892-899.
12. Gabizon A, Papahadjopoulos D.The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta, 1992; 1103:94-100.
13. Ahmad I, Allen TM. Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro.Cancer Res, 1992; 52:4817-4820.
14. Kye-Il J, Liang X, Shhuanglong L, Yarong L, Chi- Lin L, Peter SC, Michael KW, Zibo L, Pin W. Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs. Biomaterials, 2013; 34:3098-3109.
15. Jack S, Zhu FZ. Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery. Patent Cooperation Treaty (PCT), WO 2009091531 A2, 2009.
16. Seo S, Lee J, Choi EJ, Kim EJ, Song JY, Kim J. Polydiacetylene Liposome Microarray Toward Influenza A Virus Detection: Effect of Target Size on Turn-On Signaling. Macromol Rapid Comm, 2013; 34(9):743-748.
17. Pippa N, Pispas S, Demetzos C. The imaging and the fractal metrology of chimeric liposomal Drug Delivery nano Systems: the role of macromolecular architecture of polymeric guest. J Liposome Res, doi:10.3109/08982104.2014.891232.
18. Fugit KD, Anderson BD. The role of pH and ringopening hydrolysis kinetics on liposomal release of topotecan. J Control Rel, 2014; 174: 88-97.
19. Li C, Tian M. Radiolabeled Liposomes as Drug Delivery Nanotheranostics. Drug Delivery Applications of Noninvasive Imaging: Validation from Biodistribution to Sites of Action. 2013, John Wiley & Sons, Inc.
20. Cern A, Barenholz Y, Tropsha A, Goldblum A. Computer-aided design of liposomal drugs: In silico prediction and experimental validation of drug candidates for liposomal remote loading. J Control Rel, 2014; 173: 125-131.
21. Chang HI, Cheng MY, Yeh MK. Clinically- Proven Liposome-Based Drug Delivery: Formulation, Characterization and Therapeutic Efficacy. Sci Rep, 2012; 1:2-8.
22. Rodriguez MA, Pytlik R, Kozak T, Chhanabhai M, Gascoyne R, Lu B, Deitcher SR, Winter JN. Vincristine sulfate liposomes injection (Marqibo) inheavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer, 2009; 115:3475- 3482.
23. Madni AU, Ahmad M, Akhtar N, Usman M. New Simultaneous High Performance Liquid Chromatographic Method for Determination of NSAIDs and Opioid Analgesics in Advanced Drug Delivery Systems and Human Plasma. World Academy of Science, Engineering and Technology (WASET), 2009; 55:158-163.
24. Riaz M. Liposomes preparation methods. Pak J Pharm Sci, 1996; 19:65-77.
25. Sprott GD, Dicaire CJ, Fleming LP, Patel GB. Stability of liposomes prepared from archaeobacterial lipids and phosphatidylcholine mixtures. Cell Matt, 1996; 6:143-155.
26. Krishnan L, Sprott GD. Archaeosome adjuvants: immunological capabilities and mechanism(s) of action. Vaccine, 2008, 26:2043-55.
27. Benvegnu T, Lemiegre, Cammas MS. New generation of liposomes called archeosomes based on natural or synthetic archael lipids as innovative formulations for drugdelivery. RecentPatDrugDeliv Formul, 2009; 3:206-220.
28. Applications of Extremophilic Archaeal Lipids in the Field of Nanocarriers for Oral/Topical Drug Delivery. Benvegnu, Thierry; Lemiegre, Loic; Dalencon, Sylvain; Jeftic, Jelena. Current Biotechnology, Volume 2, Number 4, November 2013, pp. 294-303(10)
29. Sprott GD, Choquet C, Patel GB, Irena E. Formation of stable liposomes from lipid extracts of archaebacteria (archaea).Patent Cooperation Treaty (PCT), WO9308202,1993.
30. Julie B, Sandrine CM, Pierrick A, Thierry B. Preparation and Characterization of Stealth Archaeosomes Based on a Synthetic PEGylated Archaeal Tetraether Lipid. J Drug Deliv, 2011; 2011:396068.
31. Krishnan L, Sad S, Patel GB, Sprott GD. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help. J Immunol, 2000; 165:5177-85.
32. Krishnan L, Dicaire CJ, Patel GB, Sprott GD. Archaeosome vaccine adjuvants induce strong humoral, cell mediated, and memory responses: comparison to conventional liposomes and alum. Infect Immun, 2000; 68:54-63.
33. Conlan JW, Krishnan L, Willick GE, Patel GB, Sprott GD. Immunization of mice with lipopeptide antigens encapsulated in novel liposomes prepared from the polar lipids of various Archaeobacteria elicits rapid and prolonged specific protective immunity against infection with the facultative intracellular pathogen, Listeria monocytogenes. Vaccine, 2011; 19:3509-3517.
34. Benvegnu T, Plusquellec D, G. Réthoré, M. Sachet, C. Ferec, T. Montier, P. Delépine, P. Lehn, Compounds analogous to membrane lipids in archaebacteria and liposomal compositions including said compounds. Patent Cooperation Treaty (PCT), WO2006061396, 2006.
35. Réthoré G, Montier T, Le Gall T. Archaeosomes based on synthetic tetraether-like lipids as novel versatile gene delivery systems. Chem Comm, 2007; 20:2054-2056.
36. Mannino RJ, Gould-Fogerite S, Krause-Elsmore SL, Delmarre D, Lu R. Novel encochleation methods, cochleates and methods of use. U.S. Patent, 2005/0013854, 2005.
37. Tuo J. Cochleates without metal cations as the bridging agents. WIPO Patent Application, WO/2004/012709, 2003.
38. Ruying L,Raphael JM. Amphiphilic nucleotide cochleate compositions and methods of using the same. USPTO Applicaton, 20120232260, 2008.
39. Zarif L, Jin T, Segarra I, Mannino RJ. Hydrogelisolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules. U.S. Patent, 6592894, 2003.
40. Gould-Fogerite S, Kheiri MT, Zhang F. Targeting immune response induction with cochleate and liposome based vaccines. Adv Drug Del Rev, 1998; 32:273-287.
41. Zarif L, Graybill J, Perlin D, Mannino RJ. Cochleates: new lipid based drug delivery system. J Liposome Res, 2000; 10:523-538.
42. Amram M, Richards ME, Raquel FE, Brigitte PS.Antibiotic drug delivery and potentiation. U.S. Patents, US 20120237562, 2012.
43. Ma Y, Wang Z, Zhao W, Lu T, Wang R, Mei Q, Chen T. Enhanced bactericidal potency of nanoliposomes by modification of the fusion activity between liposomes and bacterium. Int J Nanomedicine, 2013; 8: 2351-2360.
44. Garg G, Saraf S. Cubosomes: an overview. Biol Pharm Bull 2007; 30:350-3.
45. Rizwan SB, Dong YD, Boyd BJ, Rades T, Hook S.Characterization of bicontinuous cubic liquid crystalline systems of phytantriol and water using cryo field emission scanning electron microscopy (cryo FESEM). Micron, 2007; 38:478-485.
46. Wu HB, Huo DF, Jiang XG. Advances in the study of lipid-based cubic liquid crystalline nanoparticles as drug delivery system. Acta Pharm Sinica, 2008; 43:450-5.
47. Angelov B, Angelova A, Garamus VM, Drechsler M, Willumeit R, Mutafchieva R, Stěpánek P, Lesieur S.Earliest stage of the tetrahedral nano channel formation in cubosome particles from unilamellar nano vesicles.Langmuir, 2012; 28:16647-55.
48. Di B, Tao Z, James BM, Bi-Botti CY. Formulation of Dacarbazine-loaded Cubosomes. Part III. Physicochemical Characterization. AAPSPharmSciTech, 2010; 11:1243-1249.
49. Rizwan SB, Assmus D, Boehnke A, Hanley T, Boyd BJ, Rades T, Hook S. Preparation of phytantriol cubosomes by solvent precursor dilution for the delivery of protein vaccines. Eur J Pharm and Biopharm, 2011; 79:15-22.
50. Rattanapak T, Young K, Rades T, Hook S. Comparative study of liposomes, transfersomes, ethosomes and cubosomes for transcutaneous immunization: characterization and in vitro skin penetration. J Pharm Pharmacol, 2012; 64:1560- 1569.
51. Yang Z, Tan Y, Chen M, Dian L, Shan Z, Peng X, Wu C.Development of Amphotericin B-Loaded Cubosomes Through the SolEmuls Technology for Enhancing the Oral Bioavailability. AAPS PharmSciTech, 2012; 13:1483-91.
52. 25-35-treated rats following intranasal administration. Eur J Pharm and Biopharm, 2012; 80:368-78.
53. Fraser SJ, Mulet X, Martin L, Praporski S, Mechler A, Hartley PG, Polyzos A, Separovic F.Surface immobilization of bio-functionalized cubosomes: sensing of proteins by quartz crystal microbalance. Langmuir, 2012; 28:620-7.
54. Hinton TM, Grusche F, Acharya D, Shukla R, Bansal V, Waddington LJ, Monaghan P, Muir BW. Bicontinuous cubic phase nanoparticle lipid chemistry affects toxicity in cultured cells. Toxicol Res, 2014; 3:11-22.
55. Fan Chao, Li X, Zhou Y, Zhao Y, Ma S, Li W, Liu Y, Li G. Enhanced Topical Delivery of Tetrandrine by Ethosomes for Treatment of Arthritis. Biomed Res Int, 2013; 2013:161943.
56. Xiao-Jing X, Lang Y, Yi Y, Bai-Yu Z, Qiu-He S, Jun D, Fei H.Study of the biological function and penetration pathways of the mouse epidermal growth factor ethosomal delivery system.Exp Dermatol,2011; 20:943-958.
57. Touitou E. Composition of applying active substance to or through the skin. US patents, US 5540934, 1996.
58. Touitou E. Drug delivery across the skin. Exp Opinion Biol Ther, 2002; 2002:723-733.
59. Verma DD, Fahr A. Synergistic penetration effect of ethanol and phospholipids on the topical delivery of Cyclosporin A. J Control Release, 2004; 97:55-66.
60. Poonam V, Pathak K. Therapeutic and cosmeceutical potential of ethosomes: An overview.J AdvPharm Tech Res, 2010; 1:274-282.
61. Mishra D, Mishra PK, Dubey V, Nahar M, Jain NK. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes. J Control Rel, 2007; 33:424-33.
62. Anitha P, Ramkanth S, Uma-Sankari K, Alagusundaram M, Gnanapraksah K, Devaki DP, Indira PR. Ethosomes - A noninvasive vesicular carrier for transdermal drug delivery. Int J Rev Life Sci, 2011; 1:17-24.
63. Touitou E, Godin B, Dayan N. Intracellular delivery mediated by ethosomal carrier. Biomater, 2001; 22:3055-9
64. Topical ethosomal capsaicin attenuates edema and nociception in arthritic rats. Sarwa KK, Rudrapal M, Mazumder B. doi:10.3109/10717544.2013.861041.
65. Paolino D, Lucania G, Mardente D, Alhaique F, Fresta M. Ethosomes for skin delivery of ammonium glycyrrhizinate: In vitro percutaneous permeation through human skin and in vivo antiinflammatory activity on human volunteers. J Control Release, 2005; 106:99-110.
66. Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release, 2007; 123:148-54.
67. Godin B, Touitou E. Erythromycin ethosomal systems: Physicochemical characterization and enhanced antibacterial activity. Curr Drug Deliv, 2005; 2:269-75.
68. Teerawan R. Comparative study of liposomes, transfersomes, ethosomes and cubosomes for transcutaneous immunization: characterization and in vitro skin penetration. J Pharm Pharmacol, 2012; 64:1560-1569.
69. El Maghraby GM, Williams AC.Vesicular systems for delivering conventional small organic molecules and larger macromolecules to and through human skin. Expet Opin Drug Deliv, 2009; 6:149-63.
70. Rita C, Laura R, Enea M, Drechsler M, Elisabetta E. Colloidal Dispersions for the Delivery of Acyclovir: A Comparative Study. Indian J Pharm Sci, 2011; 73:687-693.
71. Zhang JP, Wei YH, Zhou Y, Li YQ, Wu XA.Ethosomes, binary ethosomes and transfersomes of terbinafine hydrochloride: a comparative study. Archives Pharm Res, 2012; 35:109-17.
72. Park JE, Tan HS, Datta A, Lai RC, Zhang H, Meng W, Lim SK, Sze SK. Hypoxic Tumor Cell Modulates Its Microenvironment to Enhance Angiogenic and Metastatic Potential by Secretion of Proteins and Exosomes. Mol Cell Proteomics, 2010; 9:1085-99.
73. Sander AAK, Pieter V, Susan MD, Wouter WS, Raymond MS. Exosomemimetics: a novel class of drug delivery systems. Int J Nanomedicine, 2012; 7:1525-1541.
74. Hong T, Min H, Li-Xing Y, Yue JL, Xia G, Wen- Jing Z, Rui-Zhen J. Suppression of inflammation by tumor-derived exosomes: a kind of natural liposome packaged with multifunctional proteins. J Liposome Res, 2012; 22:346-52.
75. Johnsen KB, Gudbergsson JM, Skov MN, Pilgaard L, Moos T, Duroux M. A comprehensive overview of exosomes as drug delivery vehicles - Endogenous nanocarriers for targeted cancer therapy. Bioch Biophys Acta Rev Cancer, 2014; 1846:75-87.
76. Ruenn CL, Ronne WYY, Kok HT, Sai KL. Exosomes for drug delivery-a novel application for the mesenchymal stem cell. Biotechnology Advances, 2012; 31:543-51.
77. Karine L, Claude M, Safouane H, Sébastien R, Jean-François FP, Toshihide K, Jean-Pierre S, Bertrand P, Christian B, Michel R. Mast cell- and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization. Biochem J, 2004; 380:161-71.
78. Aaron T, Hug DLP, Alexander MS. The application of exosomes as a nanoscale cancer vaccine. Int J Nanomedicine, 2010; 5:889-900.
79. Lakhal S, Wood MJ. Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosomes nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers. BioEssays, 2011; 33:737-41.
80. Liu R, Wei X, Yao Y, Chai Q, Chen Y, Xu Y.The preparation and characterization of gas bubble containing liposomes.Conference Proceedings: IEEE Engineering in Medicine and Biology Soceity, 2005; 4:3998-4001.
81. Geers, B., De Wever, O., Demeester, J., Bracke, M., De Smedt, S. C. and Lentacker, I. (2013), Targeted Liposome-Loaded Microbubbles for Cell-Specific Ultrasound-Triggered Drug Delivery. Small, 9: 4027-4035.
82. 2 Bubbles to Induce Transient Cavitation, Lysosomal Rupturing, and Cell Necrosis. Angew Chem Int Ed, 2012; 51:10089-10093.
83. Kee PH, Kim H, Huang S, Laing ST, Moody MR, Vela D, Klegerman ME, McPherson DD. Nitric Oxide Pretreatment Enhances Atheroma Component Highlighting in Vivo with Intercellular Adhesion Molecule-1-Targeted Echogenic Liposomes. Ultrasound Med Biol, 2014; 40:1167-1176.
84. George LB, Hyunggun K, Patrick HK, Jaroslaw A, Christy K, McPherson D, Shao-Ling H. In Vivo Therapeutic Gas Delivery for Neuroprotection with Echogenic Liposomes. Circulation, 2010; 122:1578-87.
85. Bryne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Del Rev, 2008; 60:1615-1626.
86. Huang A, Kennel SJ, Huang L. Interactions of immunoliposomes with target cells. J Biol Chem 1983; 258:14034-14040.
87. Sullivan SM, Connor J, Huang L. Immunoliposomes: preparation, properties, and applications. Med Res Rev, 1986; 6:171-195.
88. Chang EH, Pirollo KF. Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent.U.S. Patents, US20100329981, 2010.
89. Vladimir P. Immunoliposomes and PEGylated Immunoliposomes: Possible Use for Targeted Delivery of Imaging Agents.Immuno Methods, 1994; 4:244-258.
90. Hood RR, Shao C, Omiatek DM, Vreeland WN, DeVoe DL. Microfluidic Synthesis of PEG- and Folate-Conjugated Liposomes for One-Step Formation of Targeted Stealth Nanocarriers. Pharm Res, 2013; 30:1597-1607.
91. Joshua G, Allen M, Deepak S, Linda AS, Raymond S, Steve PW. Anti-alpha V immunoliposome compositions, methods and uses. U.S. Patent, US 8138315, 2011.
92. Andreas W, Christoph R, Reto R, Annette O, Imke A, Richard H, Gerhard C, Christoph M.Targeting tumor-associated endothelial cells: anti-VEGFR2-immunoliposomes mediate tumorvessel disruption and inhibit tumor growth. Clin Cancer Res, 2012; 18:454-64.
93. Mamot C, Ritschard R, Wicki A, Küng W, Schuller J, Herrmann R, Rochlitz C. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. J Drug Target, 2012; 20:422-32.
94. Barrajón-Catalán E, Menéndez-Gutiérrez MP, Alberto F, Miguel S, Angela C, Vicente M. A Multipurpose Strategy in Breast Cancer Targeted Therapy.Indian J Exp Biol, 1997; 15:840-4.
95. Muzykantov VR.Immunotargeting of catalase to the pulmonary vascular endothelium.Methods in Molec Med, 2000; 25:241-54.
96. Robert CS, Jenna MR, Zhanna I, Bin W, Lee-Gau CP, Andrew CI, Deborah LC, Mohammad FK. Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J, 2009; 23:3361-7.
97. Katharina M, Ronny R, Sina F, Oliver S, Roland EK. Dual Targeting of Tumor Cells with Bispecific Single-Chain Fv-Immunoliposomes. Antibodies, 2012; 1:199-214.
98. Perrin P, Sureau P, Thibodeau L. Structural and immunogenic characteristics of rabies Immunosomes. Dev Biol Standardization, 1985; 60:483-91.
99. Koch M, Krieger ML, Stolting D, Brenner N, Beier M, Jaehde U, Wiese M, Rover HD, Bendas G. Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: Molecular mechanisms unveiled by gene expression profiling. Biochem Pharmacol, 2013; 85: 1077-1090.
100. Thibodeau L, Laval-des-Rapides Q, Armand B, Pierre N.Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane. German Patents, DE3173713, 1986.
101. Macauley MS, Pfrengle F, Rademacher C, Nycholat CM, Gale AJ, von Drygalski A, Paulson JC. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J Clin Invest, 2013; 123(7):3074-3083.
102. Kwong B, Gai SA, Elkhader J, Wittrup KD, Irvine DJ. Localized Immunotherapy via Liposome- Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity. Cancer Res, 2013; 73:1547- 58.
103. Lise T. Immunosome technology to improve antigen presentation for efficient and safe viral vaccines Mol Eng, 1991; 1:275-293.
104. Cryz SJ, Que JU, Gluck R, A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans, Vaccine 14 (1996) 1381-3.
105. Masoumeh TK, Abbas J, Shenagari M, Hamidreza H, Farzaneh S, Fatemeh A, Reza S.Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge. Antiviral Res, 2012; 95:229-236.
106. H. Peter and G. S. Richard, Fusogenic Virosomes Prepared by Partitioning of Vesicular Stomatitis Virus G Protein Into Preformed Vesicle, J. Biol. Chem. 269 (1994) 4050-4056.
107. Lise T, CeLine T, Lise L. Oral Priming Followed by Parenteral Immunization with HIVImmunosomes Induce HIV-1-Specific Salivary and Circulatory IgA in Mice and Rabbits. AIDS Res Hum Retroviruses, 1992; 8:1379-1379.
108. Leb VM, Jahn-Schmid B, Kueng HJ, Schmetterer KG, Haiderer D, Neunkirchner A, Fischer DF, Hartl A, Thalhamer J, Steinberger P, Bohle B, Seed B, Pickl WF. Modulation of allergen-specific T-lymphocyte function by virus-like particles decorated with HLA class II molecules. J Allergy Clin Immunol, 2009; 124:121-128.
109. Simanouchi T, Yoshimoto N, Hiroiwa A, Nishiyama K, Hayashi K, Umakoshi H. Relationship between the mobility of phosphocholine headgroup and the protein- liposome interaction: A dielectric spectroscopic study. Coll Surf B, 2014; 16:343-350.
110. Shafique M, Meijerhof T, Wilschut J, de Haan A. Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses. PLoS One, 2013; 8:e61287.
111. Gluck R, Mischler R, Brantschen S. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest,199290 (1992) 2491-5.
112. Kueng HJ, Leb VM, Haiderer D, Raposo G, Thery C, Derdak SV, Schmetterer KG, Neunkirchner A, Sillaber C, Seed B, Pickl WF. General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. J Virol, 2007; 81:8666-8676.
113. Kersten GFA, Crommelin DJA. Liposomes and ISCOMs. Vaccine, 2003; 21:915-920.
114. Pham HL, Shaw PN, Davies NM. Preparation of immuno-stimulating complexes (ISCOms) by ether injection. Int J Pharm, 2006; 310:196-202.
115. McArthur J, Schulze K, Chin J, Currie BJ, Sriprakash KS, Talay SR, Chhatwal GS, Guzmán CA, Walker MJ. Immune responses of a liposome/ISCOM vaccine adjuvant against streptococcal fibronectin binding protein 1 (Sfb1) in mice. Indian J Med Res, 2004; 119:115-20.
116. Madsen HB, Arboe-Andersen HM, Rozlosnik N, Madsen F, Ifversen P, Kasimova MR, Nielsen HM. Investigation of the interaction between modified ISCOMs and stratum corneum lipid model systems. Biochim Biophys Acta (BBA) Biomembr 2010; 1798:1779-89.
117. Barrán-Berdón AL, Mónica M, Clara AR, Lourdes P, María-Rosa I, Castro-Hartmann P, Alberto M, Emilio A, Elena J. Ribbon-type and clustertype lipoplexes constituted by a chiral lysine based cationic gemini lipid and plasmid DNA. Soft Matter, 2012; 8:7368-7380.
118. Alevtina D, Sonya G, George C. Efficient delivery of transgenes to human hair follicle progenitor cells using topical lipoplex. Nat Biotechnol, 2000; 18:420-423.
119. San H, Yang ZY, Pompili VJ, Jaffe ML, Plautz GE, Xu L, Felgner JH, Wheeler CJ, Felgner PL, Gao X. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther, 1993; 4:781-8.
120. Schwartz B, Ivanov MA, Pitard B, Escrioul V, Rangara R, Byk G, Wils P, Crouzetand DS. Synthetic DNA-compacting peptides derived from human sequence enhance cationic lipid-mediated genetransfer in vitro and in vivo. Gene Ther, 1999; 6:282-292.
121. Baichao M, Shubiao Z, Huiming J, Budiao Z, Hongtao L. Lipoplex morphologies and their influences on transfection efficiency in gene delivery.J Control Release, 2007; 123:184-194.
122. Mukherjee K, Sen J, Chaudhuri A. Common colipids, in synergy, impart high gene transfer properties to transfection-incompetent cationic lipids.FEBS Lett, 2005; 579:1291-300.
123. Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev, 2006; 58:32-45.
124. Tan Y, Liu F, Li Z, Li S, Huang L. Sequential Injection of Cationic Liposome and Plasmid DNA Effectively Transfects the Lung with Minimal Inflammatory Toxicity. Mol Therap, 2001; 3:673- 682.
125. Audouy S, Hoekstra D. Cationic lipid-mediated transfection in vitro and in vivo (review). Mol Membr Biol, 2001; 18:129-143.
126. Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, Ferrari M, Lalor P, Komai M, Mere R, Bell M, Brenneman K, Mateczun A, Evans T, Kaslow D, Galloway D, Hobart P. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.Proc Natl Acad Sci, USA, 2004; 101:13601-6.
127. Behfar M, Sarah E, Qinguo Z, Afzal RM, Yvonne P. Exploring the Correlation Between Lipid Packaging in Lipoplexes and Their Transfection Efficacy. Pharmaceutics, 2011; 3:848-864.
128. Yanasarn N, Sloat BR, Cui Z. Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens. Mol Pharm, 2011; 8(4): 1174-1185.
129. Majeti BK, Karmali PP, Madhavendra SS, Chaudhuri A. Example of fatty acid-loaded lipoplex in enhancing in vitro gene transfer efficacies of cationic amphiphile. Bioconjug Chem, 2005; 16:676-84.
130. Kearns MD, Patel YN, Savva M. Physicochemical characteristics associated with transfection of cationic cholesterol-based gene delivery vectors in the presence of DOPE. Chem Phys Lipids, 2010; 163:755-64.
131. Dufaÿ WA, Hillaireau H, Nascimento TL, Arpicco S, Taverna M, Ribes S, Bourge M, Nicolas V, Bochot A, Vauthier C, Tsapis N, Fattal E. Hyaluronic acid-bearing lipoplexes: Physicochemical characterization and in vitro targeting of the CD44 receptor. J Control Release,2012; 162:545-52.
132. Gaëlle B, Riccardo C, Jelena KT, Vincent D, Olivier C, Florence G, Claire W, Christine M. Ultra Magnetic Liposomes for MR Imaging, Targeting, and Hyperthermia. Langmuir, 2012; 28:11834-11842.
133. Nazila K, Andrew DM. Paramagnetic Liposome Nanoparticles for Cellular and Tumour Imaging. Int J Mol Sci, 2010; 11:1759-1776.
134. Frascione D, Diwoky C, Almer G, Opriessnig P, Vonach C, Gradauer K, Leitinger G, Mangge H, Stollberger R, Prassl R. Ultrasmall superparamagnetic iron oxide (USPIO)-based liposomes as magnetic resonance imaging probes. Int J Nanomed, 2012; 7:2349 - 2359.
135. Pallab P, Jyotsnendu G, Rinti B, Jayesh B, Dhirendra B. Preparation and characterization of manganese ferrite-based magnetic liposomes for hyperthermia treatment of cancer. J Magn Magn Mater, 2007; 311:208-15.
136. Esther A, Joachim K, Elisabeth M, Thomas S, Marcus T, Erik R. Triggered Release from Liposomes through Magnetic Actuation of Iron Oxide Nanoparticle Containing Membranes. Nano Lett, 2011; 11:1664-1670.
137. Strijkers GJ, Kluza E, Van Tilborg GA, Van der Schaft DW, Griffioen AW, Mulder WJ, Nicolay K. Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis, 2010; 3:161-73.
138. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev, 1999; 51:691-743.
139. Kamaly N, Kalber T, Kenny G, Bell J, Jorgensen M, Miller AD. A novel bimodal lipidic contrast agent for cellular labelling and tumor MRI. Org Biomol Chem, 2010; 8:201-211.
140. Kikumori T, Kobayashi T, Sawaki M,Imai T. Anti-cancer effect of hyperther mia on breast cancer by magnetite nanoparticle-loaded anti- HER2 immunoliposomes. Breast Cancer Res Treat, 2009; 113:435-41.
141. Shido Y, Nishida Y, Suzuki Y, Kobayashi T, Ishiguro N. Targeted hyperthermia using magnetite cationic liposomes and an alternating magnetic field in a mouse osteosarcoma model.J Bone Joint Surg Br, 2010; 92:580-5.
142. Anchal S, Pravin P. Recent Trends in Niosome as Vesicular Drug Delivery System. J Appl Pharm Sci, 2012; 2:20-32.
143. Nefise, O.S., Niosomes as nanocarrier systems: a review, in Reza MM, Nanomaterials and Nanosystems for Biomedical Applications, Springer Netherlands, Dordrecht,67-81, 2007.
144. Hunter CA, Dolan TF, Coombs GH, Baillie AJ. Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol, 1988; 40:161-5.
145. Yoshioka T, Sternberg B, Florence AT. Preparation and Properties of Vesicles (Niosomes) of Sorbitan Monoesters (Span-20, Span-40, Span- 60 And Span-80) And A Sorbitan Triester (Span- 85). Int J Pharm, 1994; 105: 1-6.
146. II.P. Sheena, U.V. Singh, R. Kamath, D.P. Uma, N. Udupa, Niosomal withaferin A, with better tumor efficiency. Indian J Pharm Sci, 1998; 60:45-8.
147. Moser P, Marchand AM, Labrude P, Handjani VRM, Vignerson C. Hemoglobin niosomes: Preparation, functional and physico-chemical properties, and stability. Pharma Acta Helv, 1989; 64:192-202.
148. Raja RA, Naresh GC, Pillai GK, Udupa N. Antiinflammatory activity of niosome encapsulated diclofenac sodium in arthritic rats. Indian J Pharmacol, 1994; 26:46-48.
149. Jayaraman SC, Ramachandran C, Weiner N. Topical delivery of erythromycin from various formulations: an in vivo hairless mouse study. J Pharm Sci, 1996; 85:1082-4.
150. Uchegbu IF, Double JA, Turton JA, Florence TA. Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. Pharm Res, 1995; 12:1019-24.
151. Luciani AA, Olivier JC, Clement O, Siauve N, Brillet PY, Bessoud B, Gazeau F, Uchegbu IF, Kahn E, Frija G, Cuenod CA. Glucosereceptor MR imaging of tumors: study in mice with PEGylated paramagnetic Niosomes. Radiology, 2004; 231:135-42.
152. Kawai N, Ito A, Nakahara Y, Futakuchi M, Shirai T, Honda H, Kobayashi T, Kohri K.Anticancer effect of hyperthermia on prostate cancer mediated by magnetite cationic liposomes and immuneresponse induction in transplanted syngeneic rats.Prostate, 1986;64:373-81
153. Baillie AJ, Coombs GH, Dolan TF, Laurie J. Nonionic surfactant vesicles, niosomes, as delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol, 1986;38:502- 5.
154. Arunothayanun P, Turton JA, Uchegbu IF,Florence AT. Preparation and in vitro/in vivo evaluation of luteinizing hormone releasing hormone (LHRH)-loaded polyhedral and spherical/tubular niosomes. J Pharm Sci, 1999; 88:34-8.
155. Malhotra M, Jain NK. Niosomes as Drug Carriers. Indian Drugs, 1994; 31:81-86.
156. Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson AJ.Studies in topical application of niosomally entrapped Nimesulide. J Pharm Pharmacol, 1985; 7:863-868.
157. Biswal S, Murthy PN, Sahu J, Sahoo P, Amir F. Vesicles of Non-ionic Surfactants (Niosomes) and Drug Delivery Potential. Int J Pharm Sci Nanotechnol, 2008; 1:1-8.
158. Jin Y, Wen J, Garg S, Liu D, Zhou Y, Teng L,Zhang W. Development of a novel niosomal system for oral delivery of Ginkgo Biloba extract. Int J Nanomed, 2013; 8:421-30.
159. Marsh M, Matlin K, Simons K, Reggio J, White J, Kartenbeck J, Helenius A. Are lysosomes a site of enveloped-virus penetration? Cold Spring Harbor Symp Quant Biol, 1982; 46:835-843.
160. White J, Matlin K, Helenius A. Infectious entry pathway of influenza virus in a canine kidney cell line. J Cell Biol, 1981; 89:674-679.
161. Puras G, Mashal M, Zarate J, Agirre M, Ojeda E, Grijalvo S, Eritja R, Diaz-Tahoces A, Navarrete GM, Triqueros MA, Fernandez E, Pedraz JL, A novel cationic niosome formulation for gene delivery to the retina. J Control Rel, 2014; 174:27- 36.
162. Tavano L, Gentile L, Rossi CO, Muzzalipo. Novel gel-niosomes formulations as multicomponent systems for transdermal drug delivery. Coll Surf B Biointerf, 2013; 110:281-288.
163. Schenkman S, Aranjo PS, Sesso A, Quina FH, Chaimovich H. A kinetic and structural study of two-step aggregation and fusion of neutral phospholipid vesicles promoted by serum albumin at low pH. Chem Phys Lipids, 1981; 28:165-180.
164. Garcia LAM,Shenkman S, Araujo PS,Chaimovich H. Fusion of small unilamellar vesicles induced by bovine serum albumin fragments. Braz J Med Biol Res, 1983; 16:89-96.
165. Min-Jung K, Hyo LJ, In-Ah L, In-Young K, Sung KL, Hyun-Ah C,Jin-Seok K. Preparation of pHSensitive, Long-Circulating and EGFR-Targeted Immunoliposomes. Arch Pharm Res2008; 31:539- 546.
166. Ashish G, Efrosini K. pH-Sensitive PEGylated Liposomes Functionalized With a FibronectinMimetic Peptide Show Enhanced Intracellular Delivery to Colon Cancer Cells.Curr Pharm Biotechno, 2011; 12:1135-1143.
167. Qiao-ling Z, Yi Z, Min G, Di-jia Y, Xiao-feng Z, Yang L, Jing-yu X, Ying W, Zong-lin G, Konglang X, Ai-jun Z, Wei-liang C, Lin-sen S, Xuenong Z, Qiang Z. Hepatocyte-Targeted Delivery Using pH-Sensitive Liposomes Loaded with Lactosylnorcantharidin Phospholipid Complex: Preparation, Characterization, and Therapeutic evaluation In Vivo and In Vitro. Curr Med Chem, 2012; 19:5754-5763.
168. Jerome C, Milton BY, Leaf H. pH-sensitive liposomes: Acid-induced liposome fusion; (phosphatidylethanolamine/palmitoylhomocystein e/resonance energy transfer). Biophysics, 1984; 81:1715-1718.
169. Marina SA, Francisco JA, José AT, Antonio O.New pH-sensitive liposomes containing phosphatidylethanolamine and a bacterial dirhamnolipid. Chem Phys Lipids, 2011; 164:16- 23.
170. Drummond DC, Zignani M, Leroux JC. Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res, 2000; 39:409-460.
171. Nataliya MS, Xin L, Barbora B, Andreas HF, Vyacheslav VS, Xin G. Fliposomes: pH-Sensitive Liposomes Containing a trans-2- morpholinocyclohexanol-Based Lipid That Performs a Conformational Flip and Triggers an Instant Cargo Release in Acidic Medium. Pharmaceutics, 2011; 3:379-405.
172. Carvalho J, Vieira FP, De Melo VJ, Lopes MTP, Silveira JN, Ramaldes GA, Garnier-Suillerot A, Pereira-Maia EC, De Oliveira MC. Preparation and cytotoxicity of cisplatin-containing liposomes. Braz J Med Biol Res, 2007; 40:1149-1157.
173. Banerjee S, Sen K, Pal TK, Guha SK. Poly(styrene-co-maleic acid)-based pH-sensitive liposomes mediate cytosolic delivery of drugs for enhanced cancer chemotherapy. Int J Pharm, 2012; 436:786-97.
174. Sérgio S, João NM, Cristina F, Nejat D, Maria CP. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Delivery Rev, 2004; 56:947-965.
175. Yuba E, Kojima C, Harada A, Tana, Watarai S, Kono K. pH-Sensitive fusogenic polymermodified liposomes as a carrier of antigenic proteins for activation of cellular immunity. Biomaterials, 2010; 31(5):943-51.
176. Watarai S, Iwase T, Tajima T, Yuba E, Kono K. Efficiency of pH-Sensitive Fusogenic Polymer- Modified Liposomes as a Vaccine Carrier. Sci World J, 2013; 2013: 903234.
177. Wang HW, Jiang PL, Lin SF, Lin HJ, Ou KL, Deng WP, Lee LW, Huang YY, Liang PH, Liu DZ. Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization. Acta Biomaterialia, 2013; 9:5681-5688.
178. Yuba E, Tajima N, Yoshizaki Y, Harada A, Hayashi H, Kono K. Dextran derivative-based pHsensitive liposomes for cancer immunotherapy. Biomaterials, 2014; 35:3091-3101.
179. Zheng Y, Liu X, Samoshina NM, Chertkov VA, Franz AH, Guo X, Samoshin VV. Fliposomes: pH-controlled release from liposomes containing new trans-2-morpholinocyclohexanolbased amphiphiles that perform a conformational flip and trigger an instant cargo release upon acidification. Nat Prod Commun, 2012;7(3):353-8.
180. Veselov IS, Chertkov VA, Yaroslavov AA, Grishina GV, Samoshina NM, Samoshin VV. Fliposomes: new amphiphiles based on trans-3,4- bis(acyloxy)-piperidine able to perform a pHtriggered conformational flip and cause an instant cargo release from liposomes. Tetrahedron Lett, 2013;54(41):5600-5604.
181. Carvalho AD, Vieira FP, De Melo VJ, Lopes MTP, Silveria JN, Ramaldes GA, Garnier- Suillerot A, Pereira-Maia EC, De Oliveria MC. Preparation and Cytotoxicity of Cisplatincontaining Liposomes. Braz J Med Biol Res, 2007;40:1149-1157.
182. Garg A, Kokkoli E. pH sensitive PEGylated liposomes functionalized with fibronectin-mimetic peptide show enhanced intracellular delivery to colon cancer cells. Curr Pharm Biotechnol, 2011;12(8):1135-43.
183. Sakaguchi N, Kojima C, Harada A, Kono K. Preparation of pH-sensitive poly(glycidol) derivatives with varying hydrophobicities: their ability to sensitize stable liposomes to pH. Bioconjugate Chem, 2008; 19:1040-48.
184. Yuba E, Harada A, Sakanishi Y, Kono K. Carboxylated hyperbranched poly(glycidol)s for preparation of pH-sensitive liposomes. J Control Release, 2011; 149:72-80.
185. 2 gas induced drug release from pH-sensitive liposome to circumvent doxorubicin resistant cells. Chem Comm, 2012; 48:4869-4871.
186. Regen SL, Singh A, Oehme G, Singh M. Polymerized phosphatidyl choline vesicles. Stabilized and controllable time-release carriers. Biochem Bioph Res Co, 1981; 101:131-136.
187. Qin G, Li Z, Xia R, Li F, O'Neill BE, Goodwin JT, Khan HA, Chiu W, Li KC. Partially polymerized liposomes: stable against lea kage yet capable of instantaneous release for remo te controlled drug delivery. Nanotechnology, 2011; 22:155605.
188. NoahF, Jason C, Jon ON, Elliot ML, McCabe K, Anna MW, Timothy T, Hyung GK, Bin L, James DM, Christopher TD. Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor. Sarcoma, 2012; 2012:126906.
189. Städler B, Chandrawati R, Goldie K, Caruso F. Capsosomes: Subcompartmentalizing Polyelectrolyte Capsules Using Liposomes. Langmuir, 2009; 25:6725-6732.
190. Takeoka S, Ohno H, Hayashi N and Tsuchida E. Control of release of encapsulated molecules from polymerized mixeci liposomes induced by physical or chemicd stimuli. J Control Re1 1989; 9:177-1 86.
191. Sivakumar PA, Panduranga KR. Stable Polymerized Cholesteryl Methacrylate Liposomes for Vincristine Delivery. Biomed Microdevices, 2001; 3:143-148.
192. Smith CE, Kong H. Cross-Linkable Liposomes Stabilize a Magnetic Resonance Contrast- Enhancing Polymeric Fastener. Langmuir, 2014, 30 (13), pp 3697-3704.
193. Roney CA, Xu B, Xie J, Yuan S, Wierwille J, Chen CW, Chen Y, Griffiths GL. Summers RM. Rh-I-UEA-1 polymerized liposomes target and image adenomatous polyps in the APC (Min/+) mouse using optical colonography. Mol Imaging, 2011; 10:305-16.
194. Hongming C, Vladimir T, Robert L. Polymerized liposomes as potential oral vaccine carriers: Stability and bioavailability. J Control Release, 1996; 42:263-272.
195. Amit K, Satya S, Meriong Z, Alison M, Chengzhi C. Localization of antimicrobial peptides on polymerized liposomes leading to their enhanced efficacy against Pseudomonas aeruginosa. Mol Biosys, 2011; 7:711-713.
196. Hongming C, Robert SL. Polymerized Liposomes Targeted to M Cells and useful for Oral or Mucosal Drug Delivery. U.S.Patents, US 6060082, 2000.
197. Chengzhi C, Guoting Q, Amit K. Compositions and methods for making and using multifunctional polymerized liposomes. U.S. Patents, US 20090162424, 2009.
198. Shiyong Z, Yan Z. Controlled Release from Cleavable Polymerized Liposomes upon Redox and pH Stimulation. Bioconjugate Chem, 2011; 22:523-528.
199. Amit K, Uriel JE, Guoting Q, King L, Chengzhi C. "Clickable" polymerized liposomes as a versatile and stable platform for rapid optimization of their peripheral compositions. Chem Comm, 2010; 46:5746-5748.
200. Cabral EC, Hennies PT, Correia CR, Zollner RL, Santana MH. Preparation and characterization of diacetylene polymerized liposomes for detection of autoantibodies. J Liposome Res, 2003; 13:199- 211.
201. Payne NI, Timmins P, Ambrose CV, Ward MD, Ridgway F. Proliposomes: a novel solution to an old problem. J Pharm Sci,1986; 75:325-9.
202. Wang S, Ye T, Yang B, Yi X, Yao H. 7-Ethyl-10- hydroxycamptothecin proliposomes with a novel preparation method: optimized formulation, characterization and in-vivo evaluation. Drug Dev Ind Pharm, 2013; 39:393-401.
203. Yan-yu X, Yun-mei S, Zhi-peng C, Qi-neng P. Preparation of silymarin proliposomes: A new way to increase oral bioavailability of silymarin in beagle dogs.Int Pharm, 2006; 319:162-8.
204. Sun C, Wang J, Liu J, Qiu L, Zhang W, Zhang L. Liquid proliposomes of nimodipine drug delivery system: preparation, characterization, and pharmacokinetics. AAPS PharmSciTech, 2013; 14(1):332-8.
205. Vandana G, Ashok KB, Suman R. Formulation Development and in vitro Characterization of Proliposomes for Topical Delivery of Aceclofenac. Indian J Pharm Sci, 2008; 70:768- 775.
206. Gupta V, Barupal AK, Ramteke S. Formulation development and in vitro characterization of proliposomes for topical delivery of Aceclofenac. Indian J Pharm Sci, 2008;70(6):768-775.
207. Byung-Nak A, Shin-Keun K, Chang-Koo S. Proliposomes as an intranasal dosage form for the sustained delivery of propranolol. J Control Release, 1995; 34:203-210.
208. Elhissi AMA, Taylor KMG. Delivery of liposomes generated from proliposomes using airjet, ultrasonic, and vibrating-mesh nebulizers. J Drug Del Sci Tech, 2005; 15:261-265.
209. Katare OP, Vyas SP, Dixit VK. Effervescent granule based proliposomes of ibuprofen. J Microencapsul, 1990; 7:455-62.
210. Sharan KRB, Prabhakar RV. Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery. J Liposome Res, 2012; 22:285-294.
211. Sarbolouki MN, Parsaee S, Kosary P. Mixed micelle proliposomes for preparation of liposomes containing amphotericin B, in-vitro and ex-vivo studies. PDA J Pharm Sci Technol, 2000; 54:240- 6.
212. Janga KY, Jukanti R, Velpula A, Sunkavalli S, Bandari S, Kandadi P, Veerareddy PR. Bioavailability enhancement of zaleplon via proliposomes: Role of surface charge. Eur J Pharm Biopharm, 2012; 80:347-57.
213. Rojanarat W, Nakpheng T, Thawithong E, Yanyium N, Srichana T. Inhaled pyrazinamide proliposome for targeting alveolar macrophages. Drug Deliv, 2012; 19:334-45.
214. Kono K. Thermosensitive polymer-modified liposomes. Adv Drug Del Rev, 2001; 53:307-319.
215. Needham D, Durham NC. Temperature-sensitive liposomal formulation. U. S. Patents, US 6200598, 2001.
216. Chong-Kook K, Suk-Kyeong L,Beom-Jin L. Preparation and evaluation of temperature sensitive liposomes containing adriamycin and cytarabine.Pharmacal Research, 1993; 16:129- 133.
217. Mark JE, Arthur W, Jonathan PM, Tatsuaki T, Michael CK, Shyh DL. Ultrasound drug targeting to tumors with thermosensitive liposomes. International Ultrasonics Symposium (IUS), 2011; 2011:1-4.
218. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Delivery Rev, 2001; 53:285-305.
219. Needham D, Park JY, Wright AM, Tong J. Materials characterization of the low temperature sensitive liposome (LTSL): effects of the lipid composition (lysolipid and DSPE- PEG2000) on the thermal transition and release of doxorubicin. Faraday Discuss, 2013; 161:515- 534.
220. Al-Jamal, Wafa T, Al-Ahmady, Zahraa S, Kostarelos K. Pharmacokinetics & tissue distribution of temperature-sensitive liposomal doxorubicin in tumor-bearing mice triggered with mild hyperthermia. Biomaterials, 2012; 33:4608- 4617.
221. David N, Gopal A, Garheng K, Mark WD. A New Temperature-sensitive Liposome for Use with Mild Hyperthermia: Characterization and Testing in a Human Tumor Xenograft Model. Cancer Res, 2000; 60:1197-201.
222. de Smet M, HijnenNM, Langereis S, Elevelt A, Heijman E, Dubois L, Lambin P, Grüll H. Magnetic Resonance Guided High-Intensity Focused Ultrasound Mediated Hyperthermia Improves the Intratumoral Distribution of Temperature-Sensitive Liposomal Doxorubicin. Invest Radiol, 2013; 48:395-405.
223. Ahmed M, Liu Z, Lukyanov AN, Signoretti S, Horkan C, Monsky WL, Torchilin VP, Goldberg SN. Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology, 2005; 235:469-77.
224. Benjamin LV, Sheela A, Charles RM, Pavel SY, James RM, Marcel BB, Mark WD. In Vivo Monitoring of Tissue Pharmacokinetics of Liposome/Drug Using MRI: Illustration of Targeted Delivery. Magn Reson Med, 2004; 51:1153-1162.
225. Grüll H, Langereis S. Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound. J Control Release, 2012; 161:317-27.
226. Li L, ten Hagen TLM, Haeri A, Soullie T, Scholten C, Seynhaeve ALB, Eggermont AMM, Koning GA. A novel two-step mild hyperthermia for advanced liposomal chemotherapy. J Control Rel, 2014; 174: 202-208.
227. Ravi K, Manvir S, Rajni B, Nimrata S, Rana AC. Comparison of novel vesicular system (transferosomes, niosomes) for transdermal drug delivery. Int J Nat Prod Sci, 2012; 1:64.
228. Gregor C, Dieter G. Hydration-Driven Transport of Deformable Lipid Vesicles through Fine Pores and the Skin Barrier. Biophys J, 2003; 84:1010- 1024.
229. Rajan R, Vasudevan DT. Effects of permeation enhancers on the permeation mechanism of transferosomal gel of ketoconazole. J Adv PharmTechRes, 2012; 3:112-6.
230. Shailesh TP, Charmi GP,Chhagan NP. Transferosomes: A vesicular carrier system for transdermal drug delivery. Asian J Biochem Pharm Res, 2011; 1:507-524.
231. Ceve G. Transdermal drug delivery of Insulin with ultradeformable carriers. Clin Pharmacokinet, 2003; 42:461-174.
232. Ceve G, Blume G. Biological activity and characteristics of triamcinolone-acetonide formulated with the self-regulating drug carriers Transfersomes. Biochim Biophys Acta, 2003; 1614:156-64.
233. Maghraby GM, Williams AC, Barry BW. Skin delivery of estradiol from deformable and traditional liposomes: mechanistic study. J pharm pharmacol, 1999; 51:1123-1124.
234. Garg M, Mishra D, Agashe H, Jain NK. Ethinylestradiol loaded ultraflexible liposomes: Pharmackinetics and Pharmacodynmics. J Pharm Pharmacol, 2006; 58:459-468.